Publications by authors named "V Serebruany"
Background: Platelet Inhibition and Clinical Outcomes (PLATO) was a multicenter, randomized double-blind trial assessing efficacy and safety of ticagrelor versus clopidogrel in patients with acute coronary syndrome. The reported mortality benefit of ticagrelor in the PLATO trial has been challenged for over decade, and never confirmed in later trials.
Objective: To compare if there were any differences when deaths were reported to the FDAby the sponsors or by independent Contract Research Organizations (CRO).
Background: The incidence of stroke/TIA during annual dual antiplatelet therapy (ADAPT) for acute coronary syndrome (ACS) remains high. Some evidence suggests that shorter than ADAPT may diminish such risk, still providing adequate vascular protection. However, the precise timing of strokes/TIA occurrences during ADAPT is unclear but may be important for determining optimal preventive treatment duration.
View Article and Find Full Text PDFBackground: Cilostazol as an adjunct to dual antiplatelet therapy (DAPT) postcoronary stenting may further reduce vascular occlusion risks. The aim of this study was to assess the impact of cilostazol on high residual platelet reactivity (HRPR) in patients undergoing drug-eluting coronary stent implantation.
Methods: In a randomized, open-label, single-center, prospective study, the degree of platelet inhibition by cilostazol 100 mg twice daily was assessed on top of conventional DAPT compared with standard clopidogrel and low-dose aspirin combination in poststent patients with HRPR.
Article Synopsis
- Excess mortality remains a major concern even with dual antiplatelet therapy (DAPT) following acute coronary syndrome, and shorter DAPT durations may reduce bleeding risks while still protecting vascular health.
- The study analyzed data from the PLATO trial, reviewing death occurrences during DAPT and identifying when these deaths typically happened within the first year after acute coronary syndrome.
- Results showed that most deaths occurred in the first week after the event, suggesting that exploring a treatment duration of less than 12 months for DAPT could be beneficial in reducing mortality rates.
Background: Bleeding remains a complication during dual antiplatelet therapy (DAPT) for acute coronary syndrome (ACS). Some data suggest a link between bleeding and worsened vascular outcomes. However, this association is unclear, due to omitting of minor bleedings when applying conservative scales.
View Article and Find Full Text PDF